ClinicalTrials.gg
CompletedNCT06929741T-ASES-8Updated May 7, 2025

Turkish Version of the Arthritis Self-Efficacy Scale-8

An observational study in Knee Osteoarthristis and Self Efficacy, sponsored by Bezmialem Vakif University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Bezmialem Vakif University · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

Self-efficacy is a psychosocial construct that reflects an individual's confidence in their ability to perform specific tasks, focusing more on one's belief in their abilities than on actual performance. This concept is especially important in knee osteoarthritis (KOA) management, as it can significantly influence overall health and treatment outcomes, and it is considered a modifiable trait.

KOA is one of the most common musculoskeletal disorders worldwide, substantially impacting quality of life due to symptoms such as limited mobility, chronic pain, and joint stiffness. These symptoms can hinder daily activities and potentially lead to social isolation. In patients with KOA, a strong sense of self-efficacy can improve symptom management and increase participation in physical activities. Research indicates that patients with higher self-efficacy are more likely to engage actively in rehabilitation programs and achieve their treatment goals. Consequently, various self-efficacy measurement tools have been developed to better understand patients' perceptions of their condition and the extent of their disability, which in turn aids in formulating strategies to enhance self-efficacy and optimize treatment responses.

The Arthritis Self-Efficacy Scale (ASES) is widely used to assess self-efficacy in managing pain, physical functions, and other symptoms associated with arthritis. Compared to other self-efficacy instruments, the ASES has a longstanding history and is particularly applicable to KOA. Its validity and reliability have been confirmed through several studies. Initially developed as a 20-item scale with three subscales evaluating physical function, pain, and other symptoms, a shorter version-the eight-item ASES-8-was later created. This abbreviated version includes two items from the pain subscale, four items from the other symptoms subscale, and two additional items addressing fatigue and pain prevention during daily activities. Each item is rated on a scale from 1 (very uncertain) to 10 (very certain), indicating the patient's level of confidence in managing their condition.

Although the ASES-8 has been validated in several languages, it has not yet been translated into Turkish or culturally adapted for Turkish patients with KOA. Cross-cultural adaptation of patient-reported outcome measures (PROMs) requires rigorous methodologies to ensure both accurate translation and the preservation of content validity. Reliable, valid, and culturally sensitive instruments are essential for developing effective interventions for Turkish-speaking patients with KOA. Therefore, this study aims to translate and cross-culturally adapt the ASES-8 into Turkish and evaluate the reliability and validity of the resulting instrument.

02

Conditions studied

  • Knee Osteoarthristis
  • Self Efficacy
03

In context

Lead sponsor

Bezmialem Vakif University is the lead sponsor of 351 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study targets adult patients aged 18 years and older who have been diagnosed with knee osteoarthritis (KOA) based on the American College of Rheumatology (ACR) criteria. Participants must possess sufficient language proficiency to understand and complete the Turkish version of the ASES-8 scale and must be willing to provide informed consent. The study excludes individuals with health conditions that render them unsuitable for self-management programs, those with behavioral or cognitive impairments that could interfere with the assessment process, and patients with unstable angina or uncontrolled heart failure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of knee osteoarthritis (KOA) according to the American College of Rheumatology (ACR) criteria
  • Sufficient language skills to understand and complete the scale
  • Provision of informed consent

Exclusion criteria

Exclusion Criteria:

  • Health conditions unsuitable for a self-management program
  • Behavioral or cognitive issues that could hinder the assessment process
  • Unstable angina or uncontrolled heart failure
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with Knee Osteoarthritis (KOA)
06

What researchers measure

Primary outcomes

  1. Construct Validity and Reliability of the Turkish ASES-8

    Self-Efficacy in Knee Osteoarthritis (KOA) Management The primary outcome of our study is to assess the level of self-efficacy in managing KOA among Turkish-speaking patients. This is operationalized through the culturally adapted version of the Arthritis Self-Efficacy Scale-8 item version (ASES-8). Key Features of the Primary Outcome Measure: Instrument Overview: The ASES-8 is designed to evaluate the patient's confidence in managing key symptoms associated with KOA-including pain, functional limitations, fatigue, and pain prevention during daily activities. Unlike performance-based tests, this instrument focuses on patients' beliefs about their own abilities to manage these aspects, which is crucial for effective self-management. Measurement Details: Item Structure: The ASES-8 consists of eight items. Two items are derived from the pain subscale, four from the other symptoms subscale, and two additional items address fatigue and preventive strategies against pain during daily ac

    Time frame: 1 month

07

Study locations

1 site
  • Bezmialem Vakif University
    Istanbul, Fatih 34093, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Apr 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 16, 2025
StartActual
Apr 15, 2025
Primary completionActual
Apr 25, 2025
CompletionActual
May 1, 2025
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06929741
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Apr 15, 2025
Primary completion
Apr 25, 2025
Completion
May 1, 2025
Last update
May 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion